Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Peripheral Metabolic Effects of Somatostatin

This study has been completed.
Sponsor:
Collaborator:
The Ministry of Science, Technology and Innovation, Denmark
Information provided by (Responsible Party):
University of Aarhus
ClinicalTrials.gov Identifier:
NCT01062529
First received: January 28, 2010
Last updated: January 18, 2013
Last verified: January 2013

January 28, 2010
January 18, 2013
October 2009
February 2010   (final data collection date for primary outcome measure)
Plasma levels of glucose [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01062529 on ClinicalTrials.gov Archive Site
  • GH signalling [ Time Frame: one year ] [ Designated as safety issue: No ]
  • Serum levels of free fatty acids (FFA) [ Time Frame: one year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Peripheral Metabolic Effects of Somatostatin
Peripheral Metabolic Effects of Intra Arterial Somatostatin Infusion in Healthy Controls

The aim of this study is to investigate peripheral effects of Somatostatin on glucose metabolism and growth hormone (GH) signalling in healthy men. Eight subjects will be enrolled. The hypothesis is that Somatostatin infusion reverses insulin resistance caused by GH.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
  • Acromegaly
  • Growth Hormone Deficiency
  • Diabetes
Drug: Somatostatin
4 h of 150 microgram infusion
Other Name: somatostatin
Experimental: somatostatin
Intervention: Drug: Somatostatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8
February 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • BMI < 27 kg/m2
  • Written informed consent
  • Healthy

Exclusion Criteria:

  • Any disease
  • Any use of medications
  • Present or previous malignancy
  • Alcohol dependency
  • Allergy to trial medication
Male
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT01062529
M-2008005
No
University of Aarhus
University of Aarhus
The Ministry of Science, Technology and Innovation, Denmark
Principal Investigator: Jens Otto L Jørgensen, Professor
University of Aarhus
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP